EHA 2019 | Waldenström’s Macroglobulinemia: frontline treatment

Name: Waldenström’s Macroglobulinemia: frontline treatment
Uploaded: 2019-06-15T00:00:00.000Z
Duration: 2 min 44 s
Description: Alessandra Tedeschi, MD, of the Niguarda Cancer Center, Milan, Italy, discusses frontline treatment for Waldenström’s Macroglobulinemia. Dr Tedeschi specifically discusses the use of chemo-monotherapy, ibrutinib and bortezomib. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Alessandra Tedeschi • 15 Jun 2019

EHA 2019

Rare Diseases Waldenström’s Macroglobulinemia Bortezomib Ibrutinib

Alessandra Tedeschi, MD, of the Niguarda Cancer Center, Milan, Italy, discusses frontline treatment for Waldenström’s Macroglobulinemia. Dr Tedeschi specifically discusses the use of chemo-monotherapy, ibrutinib and bortezomib. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.